Hodgkin lymphoma: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• CD20 2
• CD19 10
• PD-1 9
• CD30 9
• PD-L1 2
• BCL-2 2
• STAT3 0
• CD47 1
• JAK 1
• MYC 2
• TP53 0
• ALK 0
• BTK 1
• CD22 0
• IL-6 0
• AKT 0
• CTLA-4 0
• mTOR 0
• PI3K 0
• PRMT5 1
• ABL1 0
• BCMA 0
• CD123 1
• CD38 0
• EZH2 0
• METTL3 0
• NOTCH1 0
• NRF2 0
• TIM-3 0
• AMPK 0
• AXL 0
• BDNF 1
• CCR5 0
• CDK4/6 0
• CXCR4 0
• FGFR 0
• FLT3 0
• GLP-1 0
• HDAC 0
• IL-15 1
• IL-17 0
• MET 0
• MMP-9 0
• NLRP3 0
• PARP 0
• PRAME 0
• SGLT2 0
• SIRT1 0
• TERT 0
• TIGIT 0
• TLR4 0
• TNF 0

EU-13 is a filter, not a ranking: it only narrows the list.

23 of 23+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL

  NCT05883449· Affimed GmbH· Updated 20 Aug 2025

  “Due to sponsor decision”Registry text, quoted unchanged. Source

• Withdrawn

  Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas

  NCT04952584· Baylor College of Medicine· Updated 7 Sept 2023

  “Study was not activated”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 5
• Mendelian Randomization Analysis 6
• CRISPR-Cas Systems 1
• Gene Expression Profiling 14
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 5
• Metabolomics 1
• Flow Cytometry 9
• Immunohistochemistry 19
• Liquid Biopsy 1
• Circulating Tumor DNA 6
• Xenograft Model Antitumor Assays 20
• Positron-Emission Tomography 21
• Magnetic Resonance Imaging 18
• Machine Learning 11
• Deep Learning 3
• Cohort Studies 30
• Genome-Wide Association Study 7

• Decoding the Heterogeneity of Diffuse Large B-Cell Lymphomas: A Comprehensive Genetic, Transcriptomic, and Phenotypic Profiling of B-Cell Lymphoma Cell Lines.

  Hematol Oncol, Sept 2026

• Targeted Transcriptomic Profiling Identifies Biomarkers and Molecular Features Associated With Immunotherapy Response in Classic Hodgkin Lymphoma.

  Mod Pathol, Aug 2026

• Single-cell sequencing uncovers clonal dynamics profiles and therapeutic resistance biomarkers in relapsed and refractory peripheral T-cell lymphoma.

  Front Immunol, Jul 2026

• Multidimensional Characterization of Tumor-Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes.

  Cancer Discov, May 2026

• Disordered differentiation and cellular senescence in pediatric Hodgkin Reed-Sternberg cells.

  Blood Adv, Apr 2026

• E2F Accelerates the Proliferation of B-Cell Non-Hodgkin Lymphomas by Upregulating Cell-Cycle Genes.

  Curr Med Sci, Apr 2026

• Transcriptome sequencing of Hodgkin lymphoma Hodgkin and Reed-Sternberg cells reveals escape from NK cell recognition and an unfolded protein response.

  Blood Cancer J, Apr 2026

• Spatial transcriptomics unveils immune cellular ecosystems associated with patient survival in diffuse large B-cell lymphoma.

  Oncoimmunology, Apr 2026

• Identification of plasma exosome circRNA as potential novel biomarkers for DLBCL and circrna-miRNA-mRNA network analysis.

  Clin Exp Med, Apr 2026

• Machine learning based on clinical and gene expression data assists in survival prediction and treatment optimization for diffuse large B-Cell lymphoma patients.

  Ann Hematol, Feb 2026

See which targets of this disease your abstract mentions, and go to the people working on them.